Behçet’s disease (BD) is a complex and systemic inflammatory syndrome; from a clinical point of view, it is a vasculitis that presents heterogeneous phenotypes. Genital and oral ulcers are the first and most common manifestations. Bilateral uveitis and cutaneous involvement are also present with a relatively high frequency and there are occasional manifestations in other organs or systems, such as the nervous system. Gender distribution is variable among countries, but unlike other immune-mediated diseases, there is not a predominance of females among affected subjects. BD is, in general, a rare disease although its prevalence is higher along the old “Silk Road”, especially in Turkey (up to 370 cases per 100000 population). The pathogenic mechanisms of BD remain unknown, although there is accumulated evidence of genetic predisposition and data suggesting that an aberrant immune response to certain infectious agents and some environmental factors may trigger the disease. The first described genetic factor associated with the disease was HLA-B*51, which is present in upto 60% of patients. More recently, genome wide association studies (GWAS) reinforce HLA-B*51 as the most important genetic factor in susceptibility to this disease.
Intended Use
The NamuPlex HLA-B*51 Real-time PCR Kit is an in vitro diagnostic test using real-time PCR intended for the qualitative detection of nucleic acid to determine the presence or absence of the B*51 gene, an HLA-B allele, in blood(EDTA) from humans which provides information on Behcet's disease.
NamuPlex™
HLA-B*51 Real-time PCR Kit
Cat. GNT-2002-1
Korea MFDS
Intended Use
Targets
Workflow
Results